ArticleNature2024
Probiotic neoantigen delivery vectors for precision cancer immunotherapy.
Abstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 121 papers.
0numbers the graph read from it
0cells of the map it votes in
121citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
121 citing papers in PubMed.
- Engineered probiotics couple photothermal cuproptosis with biomechanical disruption and immune activation.Bioactive materials · 2027Article
- Leveraging the bacteria for enhanced cancer immunotherapy: from a perspective of synthetic biology.Cancer biology & therapy · 2026Review
- Multi-omics analysis of saccharomyces boulardii supplementation reveals coordinated microbiome, metabolic, and immune signaling changes accompanying tumor suppression.Gut microbes · 2026Article
- Engineered bacterial therapeutics from synthetic biology to clinical translation: A multi-database scientometric analysis, 2000-2026.Human vaccines & immunotherapeutics · 2026Review
- Lyophilized bacteria-infected tumor cells for targeted immunotherapy of lung metastases and associated fibrosis.Bioactive materials · 2026Article
- Metal-organic framework nanovaccines for systemic tumour regression.Nature biomedical engineering · 2026Article
- Engineering Salmonella as an immune-metabolic modulator of the tumor microenvironment.Trends in biotechnology · 2026Review
- Engineered probiotic-propelled micro-robot as biological truck for deep tumor penetration and treatment.Materials today. Bio · 2026Article
- Engineering an arginine-nitric oxide circuit inTranslational cancer research · 2026Review
- Targeting cancer-associated fibroblasts: therapeutic strategies, translational challenges, and future perspectives.Journal of hematology & oncology · 2026Review
- An engineered probiotic Escherichia coli Nissle 1917 strain for Amuc_1100 delivery in a CT26 colorectal tumor model.Probiotics and antimicrobial proteins · 2026Article
- Firewalled synthetic commensal blocks horizontal gene transfer in the gut.bioRxiv : the preprint server for biology · 2026Article
- Engineered probiotics for tumor-targeted combination chemoimmunotherapy.Science translational medicine · 2026Article
- Current landscape and future directions of neoantigen vaccines: A new era of personalized cancer immunotherapy.Innovation (Cambridge (Mass.)) · 2026Review
- Programmable engineered bacteria manipulate metabolism and remodel the TME in situ for enhancing adoptive cell therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Bacterial engineering for cancer therapy.Nature cancer · 2026Review
- Article
- CD11b agonist GB1275 potentiates oncolytic bacterial therapy against pancreatic cancer in mouse tumor models.Nature communications · 2026Article
- Synthetically engineered probiotic suppresses colorectal cancer via inhibition of Wnt/β-catenin signaling.Cell reports. Medicine · 2026Article
- Therapeutic bacteria-trained NK cells confer long-term protection against cancer metastasis.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
61 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Andrew Redenti *Department of Microbiology & Immunology, Vagelos College of Physicians and Surgeons of Columbia University, New York, NY, USA.ORCID 0009-0001-3802-4927
Jongwon Im *Department of Biomedical Engineering, Columbia University, New York, NY, USA.ORCID 0000-0002-3660-2770
Benjamin RedentiDepartment of Microbiology & Immunology, Vagelos College of Physicians and Surgeons of Columbia University, New York, NY, USA.
Fangda LiDepartment of Microbiology & Immunology, Vagelos College of Physicians and Surgeons of Columbia University, New York, NY, USA.
Mathieu RouanneDepartment of Microbiology & Immunology, Vagelos College of Physicians and Surgeons of Columbia University, New York, NY, USA.
Zeren ShengDepartment of Biomedical Engineering, Columbia University, New York, NY, USA.
William SunDepartment of Biomedical Engineering, Columbia University, New York, NY, USA.
Candice R GurbatriDepartment of Biomedical Engineering, Columbia University, New York, NY, USA.
Shunyu HuangDepartment of Biomedical Engineering, Columbia University, New York, NY, USA.
Meghna KomaranchathDepartment of Biomedical Engineering, Columbia University, New York, NY, USA.ORCID 0009-0001-0329-7204
YoungUk JangDepartment of Biomedical Engineering, Columbia University, New York, NY, USA.ORCID 0009-0008-1479-7432
Jaeseung HahnDepartment of Biomedical Engineering, Columbia University, New York, NY, USA.
Edward R BallisterDepartment of Microbiology & Immunology, Vagelos College of Physicians and Surgeons of Columbia University, New York, NY, USA.
Rosa L VincentDepartment of Biomedical Engineering, Columbia University, New York, NY, USA.
Ana VardoshivilliDepartment of Biomedical Engineering, Columbia University, New York, NY, USA.
Tal DaninoDepartment of Biomedical Engineering, Columbia University, New York, NY, USA. td2506@columbia.edu.ORCID 0000-0003-2713-7659
Nicholas ArpaiaDepartment of Microbiology & Immunology, Vagelos College of Physicians and Surgeons of Columbia University, New York, NY, USA. na2697@cumc.columbia.edu.ORCID 0000-0002-0657-0528
Funding
Training in Cellular, Molecular and Biomedical Studies (CMBS)T32GM145766 · NIGMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Rebecca Anne Haeusler, RONALD K. LIEM · 2022 to 2026
$4.1MModulation of the tumor microenvironment with probiotic therapiesR01CA249160 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI ARPAIA, NICHOLAS, DANINO, TAL · 2020 to 2024
$3.0MEngineering immunotherapeutic probiotics to mitigate irAEU01CA247573 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI ARPAIA, NICHOLAS, DANINO, TAL · 2020 to 2024
$2.9MTreating colon cancer by regulating intestinal immunity through microbial metabolismR01CA259634 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ARPAIA, NICHOLAS · 2021 to 2025
$2.8MFive-laser Aurora spectral flow cytometerS10OD030282 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CREUSOT, REMI J · 2022 to 2022
$361kProgrammable biohybrid system for cancer therapyK99CA283259 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HAHN, JAESEUNG · 2024 to 2025
$344kNCI NIH HHS K99 CA283259NCI NIH HHS R01 CA249160NCI NIH HHS R01 CA259634NCI NIH HHS U01 CA247573NIGMS NIH HHS T32 GM145766NIH HHS S10 OD030282
Abstract
Microbial systems have been synthetically engineered to deploy therapeutic payloads in vivo
Indexed as
Antigens, NeoplasmCancer VaccinesEpitopesEscherichia coliImmunotherapyNeoplasmsPrecision MedicineProbioticsAnimalsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell Line, TumorCross-PrimingDendritic CellsFemaleHumansAntigens, NeoplasmCancer VaccinesEpitopes
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.